Cover Image
市場調查報告書

高草酸鹽尿症:開發中產品分析

Hyperoxaluria - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 360909
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
高草酸鹽尿症:開發中產品分析 Hyperoxaluria - Pipeline Review, H1 2016
出版日期: 2016年05月25日 內容資訊: 英文 53 Pages
簡介

本報告提供高草酸鹽尿症治療藥的開發情形相關調查分析,提供您開發中產品概要,參與治療藥開發的主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

高草酸鹽尿症概要

治療藥的開發

  • 開發中產品的概要

高草酸鹽尿症:企業開發中的治療藥

高草酸鹽尿症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

高草酸鹽尿症:企業開發中的產品

高草酸鹽尿症治療藥的開發企業

  • Allena Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Dicerna Pharmaceuticals, Inc.
  • Digna Biotech, S.L.
  • OxThera AB

高草酸鹽尿症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

高草酸鹽尿症:最近的開發平台趨勢

高草酸鹽尿症:暫停中的計劃

高草酸鹽尿症:開發中止的產品

高草酸鹽尿症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8089IDB

Summary

Global Markets Direct's, 'Hyperoxaluria - Pipeline Review, H1 2016', provides an overview of the Hyperoxaluria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hyperoxaluria
  • The report reviews pipeline therapeutics for Hyperoxaluria by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hyperoxaluria therapeutics and enlists all their major and minor projects
  • The report assesses Hyperoxaluria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hyperoxaluria

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hyperoxaluria
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hyperoxaluria pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hyperoxaluria Overview
  • Therapeutics Development
    • Pipeline Products for Hyperoxaluria - Overview
  • Hyperoxaluria - Therapeutics under Development by Companies
  • Hyperoxaluria - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hyperoxaluria - Products under Development by Companies
  • Hyperoxaluria - Companies Involved in Therapeutics Development
    • Allena Pharmaceuticals, Inc.
    • Alnylam Pharmaceuticals, Inc.
    • Dicerna Pharmaceuticals, Inc.
    • Digna Biotech, S.L.
    • OxThera AB
  • Hyperoxaluria - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALLN-177 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALLN-230 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-GO1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DB-027 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DCR-PH - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DCRPH-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oxabact - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hyperoxaluria - Recent Pipeline Updates
  • Hyperoxaluria - Dormant Projects
  • Hyperoxaluria - Discontinued Products
  • Hyperoxaluria - Product Development Milestones
    • Featured News & Press Releases
      • May 13, 2016: Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1
      • May 05, 2016: FDA Grants Orphan Drug Designation to Allena's Investigational Therapy for the Treatment of Pediatric Hyperoxaluria
      • Feb 10, 2016: Allena Pharmaceuticals Initiates Patient Treatment in Third Phase 2 Trial of ALLN-177 for Secondary Hyperoxaluria
      • Dec 21, 2015: Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1 in Healthy Volunteers
      • Nov 12, 2015: Allena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ALLN-177 Program at American Society of Nephrology Kidney Week
      • Nov 04, 2015: Allena Pharmaceuticals to Present Phase 2 Data on ALLN-177 Program at ASN Kidney Week 2015
      • Sep 02, 2015: Dicerna Pharmaceuticals Submits Investigational New Drug Application for DCR-PH1, an Investigational Therapy for Primary Hyperoxaluria Type 1 (PH1)
      • Aug 06, 2015: EMA Grants Orphan Drug Designation to DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1
      • Aug 04, 2015: Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria
      • Apr 23, 2015: FDA Grants Orphan Drug Designation for DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hyperoxaluria, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Hyperoxaluria - Pipeline by Allena Pharmaceuticals, Inc., H1 2016
  • Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016
  • Hyperoxaluria - Pipeline by Digna Biotech, S.L., H1 2016
  • Hyperoxaluria - Pipeline by OxThera AB, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hyperoxaluria Therapeutics - Recent Pipeline Updates, H1 2016
  • Hyperoxaluria - Dormant Projects, H1 2016
  • Hyperoxaluria - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Hyperoxaluria, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top